Global Stereotactic Radiosurgery (SRS) Market Strategic Research Report

Scope of the Report

The global Stereotactic Radiosurgery (SRS) market size is predicted to grow from US$ 3,450 million in 2025 to US$ 5,885 million in 2032; it is expected to grow at a CAGR of 7.9% from 2026 to 2032.

Stereotactic Radiosurgery (SRS) is a non-incisional, high-precision radiation therapy technique that uses a stereotactic reference system and image guidance to deliver a highly focused, ablative dose to a clearly defined target—classically in the head—with about millimeter-level targeting accuracy. In clinical practice, “SRS” is commonly used for single-fraction treatment, while “fractionated cranial stereotactic radiosurgery”may be delivered in 2–5 fractions under the same stereotactic accuracy requirements.

Upstream components of an SRS “system” include: (1) the radiation delivery platform—gamma-ray devices (e.g., multi-source Co-60), medical linear accelerators (photon-based), or particle beam accelerators; (2) beam-shaping/collimation hardware (cones, MLC/micro-MLC, sector/secondary collimation); (3) patient immobilization and stereotactic localization hardware (frames, masks, fiducials); (4) imaging and image guidance (CT/MRI/angiography; stereoscopic X-ray, cone-beam CT, skull/fiducial tracking); and (5) treatment planning software plus dosimetry/QA tools required for commissioning and ongoing verification.

Downstream, SRS is delivered mainly in radiation oncology and neurosurgery programs (often multidisciplinary) for selected intracranial targets and, in some practice settings, spine targets when stereotactic accuracy can be maintained. Typical clinical workflow links high-resolution imaging and contouring, stereotactic setup/verification, plan optimization, and carefully protocolized QA, with the goal of maximizing target ablation while minimizing dose to adjacent critical structures.

In 2025, global sales of Stereotactic Radiosurgery (SRS) reached approximately 2,528 units, with an average global market price of around US$ 1.4 million/unit. Production capacity varies significantly among manufacturers, with gross profit margins ranging from approximately 30% to 45%.

Stereotactic radiosurgery is valued for high-dose, hypofractionated delivery with sub-millimeter targeting. It is increasingly moving from a “premium add-on” to a standard capability in radiation oncology centers, especially for brain metastases, benign intracranial tumors, vascular malformations, and selected extracranial oligometastatic cases. As survivorship improves and imaging-driven detection expands, hospitals are more likely to invest not only in SRS-capable platforms, but also in tightly integrated planning, image guidance, and quality management workflows to improve throughput and reduce inter-operator variability.

Demand is propelled by the preference for non-invasive care and the operational advantages of shorter treatment courses. On the supply side, advances in IGRT, motion management, beam shaping, and dose calculation—together with automation such as auto-contouring and plan optimization—are lowering the expertise barrier and making high-precision delivery more scalable. However, adoption can still be constrained by capital budgeting cycles, bunker and radiation shielding requirements, regulatory compliance, and the time needed to build and retain experienced physics and therapy teams.

Competition is shifting from standalone hardware differentiation toward software- and service-driven end-to-end solutions: adaptive workflows, online/remote QA, connectivity and data integration, and standardized deployment across multi-site networks. Vendors that can package clinical consistency, operational efficiency, and long-term service assurance are better positioned to win both new installations and installed-base upgrades.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Stereotactic Radiosurgery (SRS) market?

What factors are driving Stereotactic Radiosurgery (SRS) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Stereotactic Radiosurgery (SRS) market opportunities vary by end market size?

How does Stereotactic Radiosurgery (SRS) break out by Type, by Application?

This report presents a comprehensive overview of the global Stereotactic Radiosurgery (SRS) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Gamma Knife
• Linear Accelerator (Linac)
• Proton Beam Therapy

Segment by Fractionation Scheme

• Single-fraction SRS
• Hypofractionated Cranial SRS

Segment by Image Guidance

• Stereoscopic X-ray Guidance
• Cone-beam CT (CBCT) Guidance
• Fiducial-based Image Guidance

Segment by Application

• Brain Stereotactic Radiosurgery
• Stereotactic Body Radiation Therapy (SBRT)

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Stereotactic Radiosurgery (SRS) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Brain Stereotactic Radiosurgery, Stereotactic Body Radiation Therapy (SBRT) evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact